JINYU(SH:600201)2018-10-25 16:00Financial Performance - Net profit attributable to shareholders decreased by 0.23% to CNY 681,035,562.16 for the period from January to September[7] - Operating revenue for the first nine months rose by 8.09% to CNY 1,432,022,991.59 compared to the same period last year[7] - The company reported a net profit margin improvement, with net profit for the year-to-date period reaching ¥1,681,486,441.73, compared to ¥1,155,176,427.90 in the previous year[38] - The company's net profit for Q3 2018 was approximately ¥323.09 million, an increase from ¥294.92 million in the same period last year, representing a growth of about 9.4%[42] - Total revenue for the first nine months of 2018 reached ¥16.69 million, up from ¥14.32 million in the previous year, indicating a year-over-year increase of approximately 16.6%[44] Assets and Liabilities - Total assets increased by 10.53% to CNY 6,282,001,921.62 compared to the end of the previous year[7] - Total liabilities decreased to ¥1,000,666,003.76 from ¥1,205,637,547.96, a reduction of 17.0%[34] - Shareholders' equity increased to ¥5,281,335,917.86 from ¥4,477,936,644.69, marking a growth of 17.9%[34] - Cash and cash equivalents decreased to ¥1,033,547,108.58 from ¥1,892,030,020.80, a decline of 45.4%[36] Cash Flow - Cash flow from operating activities decreased significantly by 63.01% to CNY 187,882,952.19[7] - Cash inflow from operating activities for the first nine months of 2018 was 1,055,389,033.88, down from 1,114,814,230.98 in the same period last year, representing a decrease of approximately 5.2%[48] - Net cash flow from operating activities for the first nine months of 2018 was 187,882,952.19, a significant decline from 507,951,891.57 in the previous year[48] - Cash outflow from investing activities for the first nine months of 2018 totaled 2,006,316,397.61, compared to 1,649,492,531.34 in the same period last year, indicating an increase of approximately 21.5%[48] - Net cash flow from financing activities was -504,120,176.41 for the first nine months of 2018, compared to 195,736,330.92 in the previous year[48] Investments and Acquisitions - The company acquired a 63.64% stake in Yikang Biotechnology for CNY 107.19 million, enhancing its market position[27] - Fixed assets increased by CNY 226.02 million, a rise of 56.65%, mainly due to the addition of fixed assets from the new subsidiary Liaoning Yikang[15] - Intangible assets increased by CNY 103.40 million, up 38.36%, primarily due to new intangible assets from Liaoning Yikang and non-patented technology in the biopharmaceutical sector[16] - Goodwill increased by CNY 186.97 million, attributed to the acquisition of Liaoning Yikang[17] Operational Costs and Expenses - Operating costs increased by CNY 87.39 million, a rise of 31.43%, mainly due to the cost changes from the new subsidiary Liaoning Yikang's poultry products[20] - R&D expenses increased by CNY 34.83 million, up 83.83%, primarily due to increased investment in new product development and technological innovation in the biopharmaceutical sector[20] - Total operating costs for Q3 2018 were ¥307,427,769.90, up from ¥224,103,893.19 in Q3 2017, reflecting a 37.1% increase[40] - Research and development expenses for Q3 2018 amounted to ¥45.55 million, significantly higher than ¥20.43 million in Q3 2017, reflecting an increase of about 123.5%[41] Shareholder Information - The number of shareholders reached 27,865 by the end of the reporting period[12] - The basic earnings per share for Q3 2018 was ¥0.33, compared to ¥0.29 in the same quarter last year, representing a growth of about 13.8%[42]